Antibe designs and develops new pharmaceuticals. We
focus on diseases characterized by inflammation, pain and/or vascular
dysfunction. Our drug design approach is to create new drugs by improving
existing, proven drugs.
Our technology platform enables us to chemically link an existing drug to a hydrogen
sulfide-releasing moeity. Hydrogen sulfide (H2S) is one of several so-called gaseous mediators.
Gaseous mediators are naturally occurring substances
found in the human body. Acting as neuromodulators, immunomodulators and vasodilators, gaseous
mediators such as H2S regulate fundamental cellular processes.
Antibe believes that H2S has tremendous therapeutic potential.
Antibe’s R&D is guided by a leading team of pharmaceutical
researchers and advisors. The team includes a Nobel Prize winner, high successful
entrepreneurs and senior scientists
affiliated with major research institutions worldwide.
Antibe is based in Calgary and has offices in Toronto, and researchers and
partners in the US, the UK, Canada, Italy and Brazil. Antibe is financed
by our founders, private investors, and by several research awards from the
Alberta Heritage Foundation for Medical Research.
| Calgary Office |
Antibe Therapeutics Inc.
3553-31st Street NW
Calgary, Alberta
Canada T2L 2K7 |
| Toronto Office |
Antibe Therapeutics Inc.
45 St. Clair Ave West
Suite 1100
Toronto, Ontario
Canada M4V 1K9
416-849-8115 |